A detailed history of Bleakley Financial Group, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Bleakley Financial Group, LLC holds 7,031 shares of PTGX stock, worth $334,816. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,031
Holding current value
$334,816
% of portfolio
0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$33.72 - $47.33 $237,085 - $332,777
7,031 New
7,031 $316 Million
Q3 2023

Nov 14, 2023

BUY
$16.68 - $23.66 $173,655 - $246,324
10,411 New
10,411 $174 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.34B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Bleakley Financial Group, LLC Portfolio

Follow Bleakley Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bleakley Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bleakley Financial Group, LLC with notifications on news.